Advertisement
UK markets close in 5 hours 30 minutes
  • FTSE 100

    8,448.82
    +67.47 (+0.81%)
     
  • FTSE 250

    20,673.47
    +142.17 (+0.69%)
     
  • AIM

    787.86
    +4.16 (+0.53%)
     
  • GBP/EUR

    1.1622
    +0.0011 (+0.10%)
     
  • GBP/USD

    1.2529
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    50,359.95
    +1,487.57 (+3.04%)
     
  • CMC Crypto 200

    1,306.42
    -51.59 (-3.80%)
     
  • S&P 500

    5,214.08
    +26.41 (+0.51%)
     
  • DOW

    39,387.76
    +331.36 (+0.85%)
     
  • CRUDE OIL

    79.73
    +0.47 (+0.59%)
     
  • GOLD FUTURES

    2,379.00
    +38.70 (+1.65%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,823.58
    +136.98 (+0.73%)
     
  • CAC 40

    8,249.20
    +61.55 (+0.75%)
     

Will Moderna’s Tenure on the S&P 500 Index Be Short-Lived?

Moderna (NASDAQ: MRNA) is now officially a member of the S&P 500. In this Motley Fool Live video recorded on July 21, 2021, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss whether or not Moderna's tenure on the S&P 500 index will be short-lived. Let's go over to Moderna, which is now officially, I think today, a member of the S&P 500 Index.